Clinical Trials
7 trialsNCT00030446 2020-04-08
Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00059787 2015-12-01
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00126542 2014-05-14
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00263822 2013-08-27
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00030498 2013-01-16
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT00063895 2013-01-09
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00217529 2010-09-21
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Completed